Post Profile






Health Canada Approves Merck’s Mavenclad to Treat RRMS

Canadians with relapsing-remitting multiple sclerosis (RRMS) can now receive Merck’s Mavenclad (cladribine tablets), now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay disease progression. Merck expects the drug to be commercially available by early January 2018 throughout Canada, which has the world’s highest MS rate.
read more

share

Related Posts


Cladribine Tablets Reduce Risk of MS Progression and Relapse, Clinical Trial Shows

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also well-tolerated and had a good safety profile, ...

Zinbryta Approved in Canada as Once-Monthly Treatment for Relapsing MS

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Health Canada has approved Zinbryta (daclizumab) as a treatment for adults with active relapsing-remitting multiple sclerosis (RRMS), Biogen and AbbVie announced. Zinbryta is a long-acting injection therapy, self-administered monthl...

#CMSC17 – Cladribine Reduced Annual MS Relapse Rate by 55% to 57%, Trials Show

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, according to clinical trials. EMD Serono, a unit of Cladribine’s developer, Merck, presented the trial...

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended...

Mavenclad Reduces MS Relapses by Reseting the Immune System

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

New analyses of how Merck’s Mavenclad (cladribine tablets) act to treat relapsing multiple sclerosis (MS) give researchers an entirely new picture of immune processes leading to the disease. Data showed that the drug lowers both imm...

Comments


Copyright © 2016 Regator, LLC